Valuation: PharmaEngine, Inc.

Market Cap 9.15B 282M 247M 228M 210M 396M 27.2B 404M 2.72B 1.07B 13.32B 1.06B 1.04B 45.86B P/E 2024
7.42x
P/E 2025 26.2x
Enterprise Value 4.48B 138M 121M 111M 103M 194M 13.31B 198M 1.33B 524M 6.52B 519M 508M 22.43B EV / Sales 2024
3.61x
EV / Sales 2025 5.97x
Free-Float
61.82%
Yield 2024
6.64%
Yield 2025 2.84%
1 day-4.07%
1 week-1.24%
Current month+4.43%
1 month+12.74%
3 months+8.15%
6 months-10.41%
Current year-9.52%
1 week 63.5
Extreme 63.5
68.4
1 month 55.8
Extreme 55.8
68.4
Current year 53
Extreme 53
74
1 year 53
Extreme 53
81.5
3 years 53
Extreme 53
123
5 years 53
Extreme 53
150.5
10 years 33.1
Extreme 33.1
212.51
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 17/05/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 19/01/2018
Director/Board Member - 13/06/2019
Director/Board Member - 15/05/2018
Change 5-day change 1-year change 3-year change Capi.($)
-4.07%-1.24%-15.52%-27.78% 296M
-1.29%-2.54%-0.35%+4.30% 49.7B
+3.90%-0.39%+376.72%+599.59% 38.09B
-1.70%+4.46%+7.46%+57.67% 35.29B
-2.01%-0.76%+26.35%-6.83% 35.13B
+0.06%+1.56%+4.41%+27.42% 27.22B
+0.46%-3.49% - - 16.14B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+2.15%+16.24%+19.12% 13.89B
0.00%+1.36%+15.74%-30.62% 13.02B
Average -0.39%-0.85%+55.50%+84.47% 24.41B
Weighted average by Cap. -0.15%-0.64%+75.09%+119.55%

Financials

2024 2025
Net sales 2.52B 77.87M 68.05M 62.79M 57.88M 109M 7.5B 112M 751M 295M 3.67B 292M 286M 12.64B 911M 28.12M 24.58M 22.68M 20.91M 39.4M 2.71B 40.28M 271M 107M 1.33B 106M 103M 4.57B
Net income 1.75B 54.03M 47.22M 43.57M 40.16M 75.7M 5.2B 77.38M 521M 205M 2.55B 203M 198M 8.77B 388M 11.96M 10.45M 9.65M 8.89M 16.76M 1.15B 17.13M 115M 45.35M 564M 44.92M 43.94M 1.94B
Net Debt -3.85B -119M -104M -95.9M -88.39M -167M -11.45B -170M -1.15B -451M -5.61B -447M -437M -19.31B -4.67B -144M -126M -116M -107M -202M -13.89B -207M -1.39B -547M -6.8B -542M -530M -23.42B
Logo PharmaEngine, Inc.
PharmaEngine Inc is a Taiwan-based company primarily engaged in new drug development. The main business is the research and development of various cancer drugs. ONIVYDE is a novel and stable encapsulated form of the marketed chemotherapy drug irinotecan in a long-circulating nanoliposome for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. It has received marketing approvals in Taiwan, the United States, the European Union, Singapore, South Korea, Japan, China and other regions. PEP07, a checkpoint kinase 1 (CHK1) inhibitor, which targets the deoxyribonucleic acid damage response (DDR) network, is in Phase 1 clinical trial stage and its target is to treat hematologic cancers such as acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), and solid tumors.
Employees
45
Date Price Change Volume
17/07/26 NT$63.70 -4.07% 931,555
16/07/26 NT$66.40 -1.48% 789,813
15/07/26 NT$67.40 +4.33% 1,876,896
14/07/26 NT$64.60 -2.12% 880,657
13/07/26 NT$66.00 +2.33% 2,324,866
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4162 Stock